Takeda Pharmaceutical Company Limited
TAK
$14.82
-$0.37-2.44%
| Weiss Ratings | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | C | |||
| Rating Factors | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Good | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.15 | |||
| Price History | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.33% | |||
| 30-Day Total Return | 5.41% | |||
| 60-Day Total Return | 11.01% | |||
| 90-Day Total Return | 11.18% | |||
| Year to Date Total Return | 11.85% | |||
| 1-Year Total Return | 12.00% | |||
| 2-Year Total Return | -6.38% | |||
| 3-Year Total Return | 9.74% | |||
| 5-Year Total Return | 12.71% | |||
| 52-Week High % Change | -1.17% | |||
| 52-Week Low % Change | 20.80% | |||
| Price | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $15.37 | |||
| 52-Week Low Price | $12.58 | |||
| 52-Week Low Price (Date) | Jun 20, 2024 | |||
| 52-Week High Price (Date) | Apr 03, 2025 | |||
| Valuation | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 46.28B | |||
| Enterprise Value | 79.20B | |||
| Price/Earnings (TTM) | 17.77 | |||
| Earnings Per Share (TTM) | 0.85 | |||
| Earnings Per Share Growth | 5.32% | |||
| Price/Earnings To Growth | 3.34 | |||
| Price/Sales (TTM) | 0.80 | |||
| Price/Book (Q) | 0.51 | |||
| Enterprise Value/Revenue (TTM) | 2.62 | |||
| Price | $14.82 | |||
| Enterprise Value/EBITDA (TTM) | 10.29 | |||
| Enterprise Value/EBIT | 24.41 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.59B | |||
| Dividend Yield | 3.33% | |||
| Div. Per Share (Most Recent) | $0.27 | |||
| Dividend Per Share (TTM) | $0.51 | |||
| Payout Ratio (TTM) | 143.72% | |||
| Dividend Per Share (Most Recent) | $0.27 | |||
| Company Info | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 81 3 3278-2111 | |||
| Address | -- | |||
| Website | www.takeda.com | |||
| Country | Japan | |||
| Year Founded | 1781 | |||
| Profitability | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 10.72% | |||
| Profit Margin | 4.51% | |||
| Management Effectiveness | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 2.06% | |||
| Return on Equity | 2.88% | |||
| Income Statement | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 30.24B | |||
| Total Revenue (TTM) | 30.24B | |||
| Revenue Per Share | $19.08 | |||
| Gross Profit (TTM) | 19.77B | |||
| EBITDA (TTM) | 7.69B | |||
| EBIT (TTM) | 3.24B | |||
| Net Income (TTM) | 1.37B | |||
| Net Income Avl. to Common (TTM) | 1.37B | |||
| Total Revenue Growth (Q YOY) | -0.34% | |||
| Earnings Growth (Q YOY) | -78.19% | |||
| EPS Diluted (TTM) | 0.85 | |||
| EPS Diluted Growth (Q YOY) | -78.45% | |||
| Balance Sheet | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.14B | |||
| Cash Per Share (Q) | $1.98 | |||
| Total Current Assets (Q) | 17.52B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 47.19B | |||
| Current Ratio (Q) | 1.313 | |||
| Book Value Per Share (Q) | $29.77 | |||
| Total Assets (Q) | 96.09B | |||
| Total Current Liabilities (Q) | 13.34B | |||
| Total Debt (Q) | 34.55B | |||
| Total Liabilities (Q) | 48.90B | |||
| Total Common Equity (Q) | 47.18B | |||
| Cash Flow | TAK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.68B | |||
| Cash from Financing (TTM) | -3.40B | |||
| Net Change in Cash (TTM) | 1.34B | |||
| Levered Free Cash Flow (TTM) | 4.21B | |||
| Cash from Operations (TTM) | 7.38B | |||
